

AKT1 E17K Activating Mutation in Human Breast Cancer

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Table of Contents

STUDY OBJECTIVES	7
STUDY INFORMATION	8
Overall PIs.....	8
Participating Centers	8
Data Abstraction Information	8
ELIGIBILITY CRITERIA SECTION	10
Patient ID.....	11
GENIE/SAGE Patient ID.....	11
Was there a diagnosis of breast cancer?.....	12
Was there a diagnosis of distant metastatic breast cancer?.....	12
Was there an AKT1 mutation status available?.....	12
Was there at least one biopsy with an Estrogen Receptor Positive Status?	13
Was there at least one biopsy with a HER2 Negative Status?.....	13
Eligibility Calculation - Automated	13
Form Status: Complete?.....	13
PATIENT INFORMATION SECTION	15
Patient’s Date of Birth	15
Patient’s Birth Year.....	16
Patient’s Gender.....	16
Patient’s Primary Race	17
Patient’s Secondary Race	17
Patient’s Tertiary Race	18
Patient’s Ethnicity.....	18
Patient’s Vital Status	19
Patient’s Date of Death	19
Patient’s Date of Death Interval, in Days - Automated	19
Patient’s Date of Last Follow-up.....	20
Patient’s Follow-up Date Interval, in Days - Automated	20
Form Status: Complete?.....	20

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

DIAGNOSIS INFORMATION SECTION.....	22
Primary Diagnosis of Breast Cancer Sub-Section	22
Date of Primary Diagnosis	23
Date of Primary Diagnosis Interval, in Days - Automated	24
Tumor Type [Onco-Tree Code]	24
AJCC Stage (Version 7) at Primary Diagnosis.....	25
Overall Tumor Grade.....	25
Lymphovascular Invasion – LVI.....	25
Progesterone Receptor – PR status.....	25
Estrogen Receptor – ER status	26
HER2 Status	26
Is the Oncotype DX Score Known?	27
Oncotype DX Score.....	27
Loco-regional Recurrence (LRR) Sub-Section	28
Was there any recurrence of tumor in the ipsilateral chest wall or in mastectomy scars, in the ipsilateral supraclavicular, infraclavicular, axillary, or internal mammary nodes?.....	28
Date of LRR	29
LRR Date Interval, in Days - Automated	30
Site of LRR.....	30
Distant Metastatic Diagnosis (de novo or relapsed) Sub-Section	31
Date of Radiologically Confirmed Distant Metastatic Disease	32
Distant Metastatic Disease Interval, in Days - Automated.....	33
Was a biopsy performed of metastatic site?.....	33
Did the ER/PR/HER2 status differ (positive to negative or vice versa) from primary tumor?.....	33
PR Status Change.....	34
ER Status Change.....	34
HER2 Status Change	35
Met Site: Bone.....	35
Met Site: Liver	35
Met Site: Lung	36
Met Site: Brain.....	36
Met Site: Lymph Node (do not include local or regional)	37

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Met Site: Soft Tissue.....	37
Met Site: Other Site.....	38
Met Site: Which Site?	38
Other (Non-Breast) Cancer Diagnoses Sub-Section	39
Has the patient had another (non-Breast) cancer diagnosis?	39
Number of non-Breast cancer diagnoses	39
Non-Breast Diagnosis Oncotree Code, Number 1	40
Non-Breast Diagnosis Oncotree Code, Number 2	40
Non-Breast Diagnosis Oncotree Code, Number 3	40
Form Status: Complete?	40
TUMOR SAMPLE SEQUENCING INFORMATION.....	42
Date sample was collected.....	43
Sample Date Interval – Automated	44
Sample Type	44
Date of the Sequencing Report	44
Sequence Report Date Interval - Automated	45
GENIE Sample ID (if available)	45
Sequencing Method	45
Specify Sequence Method.....	45
Progesterone Receptor – PR status of the Sequenced Sample.....	46
HER2 Status of the Sequenced Sample	46
Estrogen Receptor – ER status of the Sequenced Sample.....	46
AKT Mutation Status	47
AKT Variant 1.....	47
AKT Variant 2.....	47
ERBB2 Mutation Status	47
ERBB2 Variant.....	48
ESR1 Mutation Status.....	48
ESR1 Variant	48
PIK3CA Mutation Status	48
PIK3CA Variant	49

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Was another (breast cancer) sample sequenced in this patient?	49
TREATMENT REGIMENS	50
Primary Diagnosis: Treatment Regimen.....	50
Was Chemotherapy (CT) received after primary diagnosis date but before LRR or distant metastatic date?51	
Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?.....	52
Was this administered as part of a combination therapy with ovarian suppression or other?	52
Therapy 1.....	52
Was this administered as part of the clinical trial?	53
Therapy 1, Specify	53
Therapy 1 Start Date	53
Therapy 1 Start Interval.....	54
Therapy 1 End Date	55
Therapy 1 End Interval	56
Was drug discontinued?.....	56
Reason for Discontinuation	56
LRR: Treatment Regimens	57
Was CT received after LRR date but before distant metastatic diagnosis date?.....	57
Was HT received after LRR date but before distant metastatic diagnosis date?	58
Was this administered as part of a combination therapy with ovarian suppression or other?	58
Therapy 1.....	58
Was this administered as part of the clinical trial?	59
Therapy 1, Specify	59
Therapy 1 Start Date	59
Therapy 1 Start Interval.....	60
Therapy 1 End Date	60
Therapy 1 End Interval	61
Was drug discontinued?.....	62
Reason for Discontinuation	62
Metastatic Diagnosis: Therapy	64
Does this therapy involve a combination regimen?.....	64
How many drugs are part of the therapy?	65

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Drug 1	65
Was this administered as part of the clinical trial?	65
Was the drug AZD5363?	65
Generic name of drug	66
Therapy 1 Start Date	66
Therapy 1 Start Interval	67
Therapy 1 End Date	67
Therapy 1 End Interval	68
Was drug discontinued?	69
Reason for Discontinuation	69
Form Status: Complete?	69

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

STUDY OBJECTIVES

In a multi-center, retrospective and controlled study we plan to describe the clinicopathological features, response to standard therapies and outcome of ER + MBC patients, found to be *AKT1* E17K mutant (mt) on tumor sequencing vs those found to be *AKT1* E17K wild type (wt).

- *Primary Endpoint:* Overall Survival (OS) from date of metastatic diagnosis
- *Secondary Endpoints:*
 1. Duration on Therapy (DOT) for the first line of therapy used after metastatic diagnosis. This analysis will be repeated for the second line metastatic therapy and additional lines of therapy as sample size permits.
 2. Given the potential association of AKT mutation with response to rapalogs such as everolimus and temsirolimus, we plan to look specifically at DOT with mTOR inhibitor containing therapy across all lines of therapy in the AKT mt and wt cohorts.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

STUDY INFORMATION

Overall PIs

- David Hyman, MSK
- Lillian Smyth, MSK
- Phillipe Bedard, UHN

Participating Centers

Center	PI/Contact	Data Abstractor(s)	Data Manager
Dana-Farber Cancer Institute (DFC)	Michael Hassett, MD Deb Schrag, MD	Sindy Ortiz Pimentel	Eva Lepisto
GRR	Fabrice Andre, MD Monica Ardenos, MD	Semih Dogan	
HOP	Ben Park, MD	Ben Park, MD	Christopher Gocke, MD
MDA	Funda Meric-Bernstam, MD	Chetna Wathoo Walter Kinyua	Kenna Shaw
MSK	David Hyman, MD Lillian Smyth, MD	Odette Hauke Sarah Lendore	Natalie Blauvelt
NKI	Hugo Horlings, MD	Tessa Steenbruggen, MD Jan Hudecek	
PMH	Phillipe Bedard, MD	Lailah Ahmed Geeta Krishna	Celeste Yu
VDB	Mia Levy, MD Christine Micheel, PhD	Michele LeNoue-Newton Lucy Wang	Christine Micheel

Data Abstraction Information

REDCap URL: <https://redcap.mskcc.org/>

BaseCamp URL: <https://basecamp.com/2944763/projects/13104837/>

Process for Asking Questions During Data Collection:

1. Ask Center PI
2. Post BaseCamp Question to Group
3. Lillian will answer the question
4. Celeste will update Data Abstraction Guide to reflect answer

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

ELIGIBILITY CRITERIA SECTION

General Abstracting Notes:

1. In this section, patient data will be entered to determine whether the patient is eligible for continued data collection in the study. In order for a patient to be included in the study, the patient must meet the following criteria:
 - Invasive breast cancer
 - Distant metastatic site of breast cancer
 - AKT1 genomic mutation status (mutant or wildtype)
 - Estrogen Receptor (ER) status is positive (at least one)
 - HER2 status is negative (at least one)
2. In the eligibility form, information on each of these criteria will be recorded.
3. Prior to data entry, assign the record to a Data Access Group based on your center, using one of the following:
 - DFC
 - GTR
 - HOP
 - MDA
 - MSK
 - NKI
 - PMH
 - VDB

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Eligibility Criteria

Assign record to a Data Access Group? -- select a group --

+ Adding new Record ID 1

Record ID 1

Patient ID [Text Input]
* must provide value Locally Nominated Patient ID Linked to Patient MRN, DO NOT ENTER SITE SPECIFIC MRN!

GENIE/SAGE Patient ID: [Text Input]
* must provide value NOT GENIE/SAGE SAMPLE ID

Was there a diagnosis of breast cancer? radio Yes
radio No
* must provide value reset

Was there a diagnosis of distant metastatic breast cancer? radio Yes
radio No
* must provide value reset

Was there an AKT1 mutation status available? radio Yes
radio No
* must provide value reset

Was there at least one biopsy with Estrogen Receptor Positive Status? radio Yes
radio No
* must provide value reset

Was there at least one biopsy with a HER2 Negative Status? radio Yes
radio No
* must provide value reset

Form Status

Complete? [Incomplete v]

Save Record
Save and Continue
Save and go to Next Form
-- Cancel --

Field Label	Patient ID
REDCap Variable Name	patient_id
Field Type	text
Directives	Locally Nominated Patient ID This identifier should be maintained at the site linked to the center’s MRN in a separate place accessible only to the center’s study staff. The patients actual MRN should not be used.
Identifier?	Y
Required Field?	Y
Field Label	GENIE/SAGE Patient ID
REDCap Variable Name	genie_patient_id
Field Type	text
Directives	Record the existing GENIE/SAGE ID , if the patient’s genomic data was submitted to in the September 2016 data submission. This identifier is maintained at each center and is linked to the patient’s MRN. For more details and access to the GENIE/SAGE ID , ask

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>the Center Site PI for this project.</p> <p>If there is no existing GENIE ID, leave this field blank OR create a new GENIE ID that will continue to be used in reference to this case for future GENIE data submissions.</p>
Identifier?	Y
Required Field?	N
Field Label	Was there a diagnosis of breast cancer?
REDCap Variable Name	eligible_breastca_yn
Field Type	yesno
Directives	Record whether the patient has had a diagnosis of breast cancer.
Identifier?	N
Required Field?	Y
Field Label	Was there a diagnosis of distant metastatic breast cancer?
REDCap Variable Name	eligibile_metsdx_yn
Field Type	yesno
Directives	<p>Linked to <i>Was there a diagnosis of breast cancer?</i></p> <p>Record 'Yes' if the patient has a distant site of breast cancer that is proven either by imaging or pathology.</p> <p>Record 'No' if there is no indication in the EMR that the patient has experienced a distant site of metastasis of breast cancer.</p> <p>This data field is one of five that establishes the eligibility of the patient for the AKT1 project.</p>
Identifier?	N
Required Field?	Y
Field Label	Was there an AKT1 mutation status available?
REDCap Variable Name	elgibile_akt1_yn
Field Type	yesno
Directives	<p>Linked to <i>Was there a diagnosis of breast cancer?</i></p> <p>Record 'Yes' if the patient has an AKT1 mutation status associated with the breast cancer.</p> <p>Record 'No' if there is no indication that the patient's breast cancer an associated either an AKT1 mutation or AKT1 wildtype status.</p> <p>This data field is one of five that establishes the eligibility of the patient for the AKT1 project.</p>
Identifier?	N
Required Field?	Y

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Field Label	Was there at least one biopsy with an Estrogen Receptor Positive Status?
REDCap Variable Name	eligibile_estrogen_yn
Field Type	yesno
Directives	<p>Linked to <i>Was there a diagnosis of breast cancer?</i></p> <p>Record 'Yes' if the patient's breast cancer has ever had a pathology report stating that the breast cancer was estrogen receptor positive. The report could pertain to a biopsy or surgical procedure associated with initial diagnosis, recurrence, or distant metastasis.</p> <p>Record 'No' if there is no indication that the patient's breast cancer was ever estrogen receptor positive.</p> <p>This data field is one of five that establishes the eligibility of the patient for the AKT1 project.</p>
Identifier?	N
Required Field?	Y
Field Label	Was there at least one biopsy with a HER2 Negative Status?
REDCap Variable Name	eligibile_her2
Field Type	yesno
Directives	<p>Linked to <i>Was there a diagnosis of breast cancer?</i></p> <p>Record 'Yes' if the has ever had a pathology report stating that the breast cancer was HER2 negative. The pathology report could pertain to a biopsy or surgical procedure associated with initial diagnosis, recurrence, or distant metastasis.</p> <p>Record 'No' if there is no indication that the patient's breast cancer was ever HER2 negative.</p> <p>This data field is one of five that establishes the eligibility of the patient for the AKT1 project.</p>
Identifier?	N
Required Field?	Y
Field Label	Eligibility Calculation - Automated
REDCap Variable Name	elg_warning
Field Type	Calculated: [eligibile_breastca_yn] = '0' or [eligibile_metsdx_yn] = '0' or [eligibile_akt1_yn] = '0' or [eligibile_estrogen_yn] = '0' or [eligibile_her2] = '0'
Directives	If any of the questions in the eligibility section were answered with a 'No' the patient is not be eligible for the AKT1 study.
Identifier?	N
Required Field?	Coded
Field Label	Form Status: Complete?

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

REDCap Variable Name	
Field Type	Dropdown
Choice List	Incomplete Unverified Complete
Directives	Record 'Complete' once all of the data fields in this section have been entered and the eligibility calculation has been performed. This field will be used during data quality review. 'Incomplete' is the default choice; patients with any indication of 'Incomplete' or 'Unverified' sections are not eligible for data analysis.
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

PATIENT INFORMATION SECTION

Abstracting Notes:

1. In order to record data in this section, the patient must be eligible for the study; meaning, the patient has passed the calculated eligibility field found in the Eligibility section.
1. Much of the data fields found in this section should be provided by Sage through a download of each center’s GENIE data submission.
2. For data fields that are not pre-populated by Sage, please record the appropriate data.
3. For patients who are not found in the Genie data submission, please adhere to the NAACCR method for coding the data as applicable.

Patient Information

Re-assign this record to another Data Access Group? DFC

Editing existing Record ID 1 - 1a

Record ID: 1

Date of Birth: PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Birth Year:

Gender:

Primary Race:

Secondary Race:

Tertiary Race:

Ethnicity:

Vital Status:

Form Status

Complete?:

Save Record
Save and Continue
Save and go to Next Form
-- Cancel --

Field Label	Patient’s Date of Birth
REDCap Variable Name	dob_date
Field Type	Text
Valid Field	mm-dd-yyyy
Directives	Enter the patient’s date of birth using the following convention: mm-dd-yyyy. Please note that all components of the date must be entered.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn/fall use October (10) <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	Y
Field Label	Patient's Birth Year
REDCap Variable Name	birth_year
Field Type	text
	<p>The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.</p> <p>Linked to the <i>Patient's Date of Birth</i>.</p> <p>If the data is not pre-populated, record the 4-digit year associated with the <i>Patient's Date of Birth</i> recorded in the previous data field.</p> <p>Use the <i>Patient's Date of Birth</i> to compare the <i>Patient's Birth Year</i> with this data field; the two years should be the same.</p>
Directives	Do not leave blank.
Identifier?	N
Required Field?	Y
Field Label	Patient's Gender
REDCap Variable Name	naaccr_sex_code
Field Type	dropdown
Choice List	1, Male 2, Female 3, Other (intersex, disorders of sexual development/DSD) 4, Transsexual, NOS 5, Transsexual, natal male 6, Transsexual, natal female 99, Not stated/Unknown
Directives	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.
	Record the sex of the patient using the NAACCR sex codes.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	Do not leave blank.
Identifier?	N
Required Field?	Y
Field Label	Patient's Primary Race
REDCap Variable Name	naaccr_race_code_primary
Field Type	dropdown
Choice List	1, White 2, Black 3, American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) 4, Chinese 5, Japanese 6, Filipino 7, Hawaiian 8, Korean 10, Vietnamese 11, Laotian 12, Hmong 13, Kampuchean (Cambodian) 14, Thai 15, Asian Indian or Pakistani, NOS (code 09 prior to Version 12) 16, Asian Indian 17, Pakistani 20, Micronesian, NOS 21, Chamorro/Chamoru 22, Guamanian, NOS 25, Polynesian, NOS 26, Tahitian 27, Samoan 28, Tongan 30, Melanesian, NOS 31, Fiji Islander 32, New Guinean 88, No further race documented 96, Other Asian, including Asian, NOS and Oriental, NOS 97, Pacific Islander, NOS 98, Other 99, Unknown
Directives	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor. FOR US and Canadian Centers: Record the first mentioned race of the patient using the code used for the NAACCR Primary Race field for the GENIE clinical data submission, if applicable. FOR European Centers: Record '99, Unknown.'
Identifier?	N
Required Field?	Y
Field Label	Patient's Secondary Race
REDCap Variable Name	naaccr_race_code_primary
Field Type	dropdown
Choice List	1, White 2, Black 3, American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) 4, Chinese 5, Japanese 6, Filipino 7, Hawaiian 8, Korean 10, Vietnamese 11, Laotian 12, Hmong 13, Kampuchean (Cambodian) 14, Thai 15, Asian Indian or Pakistani, NOS (code 09 prior to Version 12) 16, Asian Indian 17, Pakistani 20, Micronesian, NOS 21, Chamorro/Chamoru 22, Guamanian, NOS 25, Polynesian, NOS 26, Tahitian 27, Samoan 28, Tongan 30, Melanesian, NOS 31, Fiji Islander 32, New Guinean 88, No further race documented 96, Other Asian, including Asian, NOS and Oriental, NOS 97, Pacific Islander, NOS 98, Other 99, Unknown
Directives	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor. FOR US and Canadian Centers: Record the second mentioned race of the patient using the code used for the NAACCR Secondary Race field for the GENIE clinical data

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>submission, if applicable.</p> <p>If the patient does not have a secondary race, enter 'No further race documented'.</p> <p>FOR European Centers: Record '99, Unknown.'</p> <p>Do not leave blank.</p>
Identifier?	N
Required Field?	Y
Field Label	Patient's Tertiary Race
REDCap Variable Name	naaccr_race_code_primary
Field Type	dropdown
Choice List	<p>1, White 2, Black 3, American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) 4, Chinese 5, Japanese 6, Filipino 7, Hawaiian 8, Korean 10, Vietnamese 11, Laotian 12, Hmong 13, Kampuchean (Cambodian) 14, Thai 15, Asian Indian or Pakistani, NOS (code 09 prior to Version 12) 16, Asian Indian 17, Pakistani 20, Micronesian, NOS 21, Chamorro/Chamoru 22, Guamanian, NOS 25, Polynesian, NOS 26, Tahitian 27, Samoan 28, Tongan 30, Melanesian, NOS 31, Fiji Islander 32, New Guinean 88, No further race documented 96, Other Asian, including Asian, NOS and Oriental, NOS 97, Pacific Islander, NOS 98, Other 99, Unknown</p>
Directives	<p>The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.</p> <p>FOR US and Canadian Centers: Record the third mentioned race of the patient using the code used for the NAACCR Tertiary Race field for the GENIE clinical data submission, if applicable.</p> <p>If the patient does not have a tertiary race, enter 'No further race documented'.</p> <p>FOR European Centers: Record '99, Unknown.'</p> <p>Do not leave blank.</p>
Identifier?	N
Required Field?	Y
Field Label	Patient's Ethnicity
REDCap Variable Name	naaccr_ethnicity_code
Field Type	dropdown
Choice List	<p>0, Non-Spanish; non-Hispanic 1, Mexican (includes Chicano) 2, Puerto Rican 3, Cuban 4, South or Central American (except Brazil) 5, Other specified Spanish/Hispanic origin 6, Spanish, NOS Hispanic, NOS Latino, NOS 7, Spanish surname only 8, Dominican Republic 99, Unknown whether Spanish or not</p>
Directives	<p>The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.FOR US and Canadian Centers: Record the ethnicity of the patient using the code used for the NAACCR Ethnicity field for the GENIE clinical data submission, if applicable.</p>

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>FOR European Centers: Record '99, Unknown whether Spanish or not.'</p> <p>Do not leave blank.</p>
Identifier?	N
Required Field?	Y
Field Label	Patient's Vital Status
REDCap Variable Name	vital_status
Field Type	dropdown
Choice List	1, Alive 2, Dead
Directives	<p>At the time of data entry, record whether the patient is '1, Alive' or '2, Dead.'</p> <p>If you cannot find a definitive death date or indication that the patient has died, record '1, Alive,' and record the date that the patient was last know to be alive in <i>Date of Last Follow-up</i>.</p>
Identifier?	N
Required Field?	Y
Field Label	Patient's Date of Death
REDCap Variable Name	death_date
Field Type	text
Valid Field	mm-dd-yyyy
Directives	<p>Linked to <i>Vital Status</i>.</p> <p>If '2, Dead' is recorded in <i>Vital Status</i>, record the date that the patient died, using the following convention: mm-dd-yyyy. Please note that all components of the date must be entered.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. <p>If '1, Alive' is recorded for <i>Vital Status</i>, leave this field blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Patient's Date of Death Interval, in Days - Automated
REDCap Variable Name	death_date_int
Field Type	Calculated: datediff([dob_date],[death_date],'d', 'mdy', false)
Directives	<p>Dependent upon <i>Date of Death</i>.</p> <p>If the <i>Date of Death</i> was entered, REDCap will calculate this field using the <i>Date of</i></p>

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>Birth.</p> <p>If the Date of Death was not entered, this data field will remain blank.</p>
Identifier?	N
Required Field?	N
Field Label	Patient's Date of Last Follow-up
REDCap Variable Name	follow_up_date
Field Type	text
Valid Field	mm-dd-yyyy
	<p>Dependent upon Vital Status.</p> <p>If '1, Alive' is recorded in Vital Status, record the date that the patient is last known to be alive. Use any data available to find this date, including: clinic notes, lab tests, procedure dates, or hospitalization dates.</p>
Directives	This date should not be approximated.
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Patient's Follow-up Date Interval, in Days - Automated
REDCap Variable Name	follow_up_date_int
Field Type	Calculated: datediff([dob_date],[follow_up_date],'d', 'mdy', false)
	<p>Dependent upon Follow-up Date.</p> <p>If the Follow-up Date was entered, REDCap will calculate this field by subtracting the Date of Birth from the Follow-up Date.</p>
Directives	If the Follow-up Date was not entered, this data field will remain blank.
Identifier?	N
Required Field?	N
Field Label	Form Status: Complete?
REDCap Variable Name	
Field Type	Dropdown
Choice List	Incomplete Unverified Complete
	<p>Record 'Complete' once all of the data fields in this section have been entered and the eligibility calculation has been performed. This field will be used during data quality review.</p>
Directives	'Incomplete' is the default choice; patients with any indication of 'Incomplete' or 'Unverified' sections are not eligible for data analysis.
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

DIAGNOSIS INFORMATION SECTION

General Abstracting Notes:

1. In order to record data in this section, the patient must be eligible for the study; meaning, the patient has passed the calculated eligibility field found in the Eligibility section.
2. This section is divided into three subsections: Primary Diagnosis, Local/Regional Recurrence, and Distant Metastasis. Each section will be presented separately.
3. The best place to find the data for this section is the relevant pathology notes.

Primary Diagnosis of Breast Cancer Sub-Section

Abstracting Notes:

1. In this section, enter data pertaining to the primary breast cancer diagnosis that resulted in the metastatic site.
2. For patients with multiple breast cancer diagnoses, enter data only on the primary cancer diagnosis thought to be associated with the metastatic disease. If you have a question about which breast cancer diagnosis is appropriate, consult with your Site PI.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Diagnosis Information Re-assign this record to another Data Access Group?

Editing existing Record ID 1 - 1a

Record ID

Primary Diagnosis (for patients with multiple breast primaries, centers will use the primary believed to have resulted in metastatic disease):

FURTHER DIRECTIONS:

- IF APPROXIMATED BY MONTH, USE FIRST OF THE MONTH AS DEFAULT.

Date of Primary Diagnosis Today M-D-Y
* must provide value
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Date of Primary Diagnosis Interval View equation

Tumor Type [Onco-Tree Code]

- Adenoid Cystic Breast Cancer (ACBC)
- Breast Carcinoma with Signet Ring (BRSRCC)
- Breast Invasive Cancer, NOS (BRCANOS)
- Breast Invasive Carcinosarcoma, NOS (CSNOS)
- Breast Invasive Ductal Carcinoma (IDC)
- Breast Invasive Lobular Carcinoma (ILC)
- Breast Mixed Ductal and Lobular Carcinoma (MDLC)
- Breast Invasive Mixed Mucinous Carcinoma (IMMC)
- Solid Papillary Carcinoma of the Breast (SPC)

reset

AJCC Stage (Version 7) at primary diagnosis:
* must provide value

Overall Tumor Grade:

LVI

PR status
POSITIVE = (>1%)

ER Status
POSITIVE = (>1%)

HER2 Status
POSITIVE= (IHC 3+ /FISH>2)

Field Label	Date of Primary Diagnosis
REDCap Variable Name	primary_dx_date
Field Type	Primary Diagnosis (for patients with multiple breast primaries, use the breast cancer primary believed to have resulted in metastatic disease)
Valid Field	mm-dd-yyyy
Directives	<p>Record the date of diagnosis for the breast cancer. The date of diagnosis should correspond to the first indication of invasive cancer based on pathology.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>known, record 15 for the day.</p> <ul style="list-style-type: none"> • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10) <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	Y
Field Label	Date of Primary Diagnosis Interval, in Days - Automated
REDCap Variable Name	primary_dx_date_int
Field Type	Calculated: datediff([dob_date],[primary_dx_date],'d', 'mdy', false)
	Dependent upon <i>Date of Primary Diagnosis</i> .
	If the <i>Date of Primary Diagnosis</i> was entered, REDCap will calculate this field by subtracting the <i>Date of Birth</i> from the <i>Date of Primary Diagnosis</i> .
Directives	Since <i>Date of Primary Diagnosis</i> is required, this data field will be filled.
Identifier?	N
Required Field?	N
Field Label	Tumor Type [Onco-Tree Code]
REDCap Variable Name	oncotree_code
Field Type	radio
Choice List	ACBC, Adenoid Cystic Breast Cancer (ACBC) BRSRCC, Breast Carcinoma with Signet Ring (BRSRCC) BRCANOS, Breast Invasive Cancer, NOS (BRCANOS) CSNOS, Breast Invasive Carcinosarcoma, NOS (CSNOS) IDC, Breast Invasive Ductal Carcinoma (IDC) ILC, Breast Invasive Lobular Carcinoma (ILC) MDLC, Breast Mixed Ductal and Lobular Carcinoma (MDLC) IMMC, Breast Invasive Mixed Mucinous Carcinoma (IMMC) SPC, Solid Papillary Carcinoma of the Breast (SPC)
	Record the OncoTree cancer type associated with the sequenced breast cancer specimen submitted to GENIE.
	Only one <i>Tumor Type</i> can be entered.
Directives	Do not leave blank.
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Field Label	AJCC Stage (Version 7) at Primary Diagnosis
REDCap Variable Name	ajcc_stage
Field Type	dropdown
Choice List	0, 0 1, 1 2, 2 3, 3 4, 4 99, UNK
Directives	Record the stage of the breast cancer using the 7th edition of AJCC; see Appendix One for more details. If more detail is known, record the more general code; for example, if Stage IIB is recorded in the EMR, record '2.'
Identifier?	N
Required Field?	Y
Field Label	Overall Tumor Grade
REDCap Variable Name	grade
Field Type	dropdown
Choice List	1, 1 2, 2 3, 3 99, UNK
Directives	Record the tumor grade. This information is usually found on the pathology report for either a biopsy or the definitive surgery of the primary tumor. If the grade is not found, record '99,UNK.'
Identifier?	N
Required Field?	N
Field Label	Lymphovascular Invasion – LVI
REDCap Variable Name	lvi
Field Type	dropdown
Choice List	1, Present 0, Absent 99, UNK
Directives	Record '1, Present' if the primary breast tumor is noted in the pathology report to have LVI. If the pathology reports are not available, but the treating physician records that the breast cancer is LVI positive record '1, Present.' If LVI is not noted, record '99,UNK.'
Identifier?	N
Required Field?	N
Field Label	Progesterone Receptor – PR status
REDCap Variable Name	pr_status
Field Type	dropdown
Choice List	1, Positive 0, Negative 99, UNK

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>Record '1, Positive' if the primary breast tumor is noted in the pathology report to be positive for progesterone receptors. If the PR status is reported as a percentage greater than 1%, record '1, Positive.'</p> <p>If PR status in the pathology report is reported as negative or as less than or equal to 1%, record '2, Negative.'</p> <p>If the pathology reports for the biopsy and/or surgery are not available, but the treating physician records that the breast cancer is progesterone receptor positive record '1, Positive.'</p>
Directives	If PR status of the primary tumor is not noted, record '99, UNK.'
Identifier?	N
Required Field?	N
Field Label	Estrogen Receptor – ER status
REDCap Variable Name	er_status
Field Type	Dropdown
Choice List	1, Positive 0, Negative 99, UNK
	<p>Record "1, Positive" if the primary breast tumor is noted in the pathology report to be positive for estrogen receptors. If the ER status is reported as a percentage greater than 1%, record '1, Positive.'</p> <p>If ER status in the pathology report is reported as negative or as less than or equal to 1%, record '2, Negative.'</p> <p>If the pathology reports for the biopsy and/or surgery of the primary breast cancer are not available, but the treating physician records that the breast cancer is estrogen receptor positive record '1, Positive.'</p>
Directives	If ER status of the primary tumor is not noted, record '99, UNK.'
Identifier?	N
Required Field?	N
Field Label	HER2 Status
REDCap Variable Name	her2_status
Field Type	Dropdown
Choice List	1, Positive 0, Negative 2, Equivocal 99, UNK
Directives	<p>Record '1, Positive' if the primary breast tumor is noted in the pathology report to be positive for HER2 by IHC at 3+ or FISH>2.</p> <p>If the HER2 is reported by IHC at 2+ and FISH was either not done or was done but reported as Equivocal record '2, Equivocal;'</p> <p>Anything else is "0, Negative", for e.g HER2 IHC 2+ but FISH is non-amplified</p>

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>If the pathology reports for the biopsy and/or surgery are not available, but the treating physician records that the breast cancer is HER2 positive record '1, Positive.'</p> <p>If HER2 status of the primary tumor is not noted in the pathology report or by physician report, record '99, UNK.'</p>
Identifier?	N
Required Field?	N
Field Label	Is the Oncotype DX Score Known?
REDCap Variable Name	oncotype_known
Field Type	yesno
Choice List	Yes No
Directives	<p>If the Oncotype DX score is recorded in the EMR, record 'Yes.'</p> <p>If the patient's chart has no mention of Oncotype DX, record 'No.'</p> <p>If the patient has had Oncotype DX, but the score is not recorded,</p> <p>If the patient did not have Oncotype DX, record 'No.'</p>
Identifier?	N
Required Field?	Y
Field Label	Oncotype DX Score
REDCap Variable Name	oncotype_score
Field Type	text
Valid Entry	0 – 100 (integer)
Directives	<p>Linked to <i>Is the Oncotype DX Score Known?</i></p> <p>If 'Yes' is recorded for <i>Is the Oncotype DX Score Known?</i>, record the Oncotype DX Score; the value of which should be a integer from 0 to 100.</p> <p>If 'No' is recorded for <i>Is the Oncotype DX Score Known?</i> leave <i>Oncotype DX Score</i> blank.</p>
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Loco-regional Recurrence (LRR) Sub-Section

Abstracting Notes:

1. The definition of a loco-regional recurrence for the AKT1 project includes: any recurrence of breast cancer in the one or more of the following:
 - Ipsilateral chest wall
 - Mastectomy scars
 - Ipsilateral supraclavicular
 - Infraclavicular nodes
 - Axillary nodes
 - Internal mammary nodes
2. This section is intended to provide detail on patients before the development of distant metastases.
 - For patients with primary diagnoses of Stage I – III breast cancer, a LRR (if it occurs at all) should occur prior to the development of a distant metastasis to enter data. If the LRR occurs after a distant metastasis, record '0, No' to the first question.
 - For patients diagnosed with Stage IV breast cancer, record '0, No' to the first question.
3. If patient has had multiple LRRs outside the setting of distant metastases, please enter information for the first recurrence below. Information on subsequent loco-regional recurrences should not be entered into this database.

Loco-regional Recurrence (LRR)

If patient has had multiple LRRs, please enter information for the first recurrence below.

FURTHER DIRECTIONS:

- IF APPROXIMATED BY MONTH, USE FIRST OF THE MONTH AS DEFAULT.
- IF DRUG HAS NOT BEEN DISCONTINUED, ENTER DATE THE DRUG WAS LAST ADMINISTERED.
- IF A PATIENT HAS HAD A "TREATMENT BREAK" - WHEREBY THEY START, STOP (FOR <=3 MONTHS) AND THEN RE-START THE SAME DRUG, ONLY RECORD START AND FINAL STOP DATE FOR THAT DRUG.
- IF MULTIPLE REASONS EXIST FOR DRUG DISCONTINUATION, POD TAKES PRECEDENCE

Was there any recurrence of tumor in the ipsilateral chest wall or in mastectomy scars, in the ipsilateral supraclavicular, infraclavicular, axillary, or internal mammary nodes?

Date of LRR Today M-D-Y
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

LRR Date Interval View equation

Site of LRR
 Local only
 Regional Lymph Nodes only
 Local and Regional Lymph Nodes

reset

Field Label	Was there any recurrence of tumor in the ipsilateral chest wall or in mastectomy
-------------	--

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	scars, in the ipsilateral supraclavicular, infraclavicular, axillary, or internal mammary nodes?
REDCap Variable Name	lrr_yn
Field Type	dropdown
Choice List	1, Yes 0, No 99, UNK
Directives	<p>If the patient has experienced a recurrence of breast cancer that occurs after the primary diagnosis period but before the diagnosis of distant metastasis, record '1, Yes.'</p> <p>If the patient has not experienced a loco-regional recurrence of breast cancer after the primary diagnosis period but before the diagnosis of distant metastasis, record '2, No.'</p> <p>If the patient's primary breast cancer was diagnosed as Stage IV, record '2, No.'</p> <p>Do not leave blank.</p>
Identifier?	N
Required Field?	Y
Field Label	Date of LRR
REDCap Variable Name	lrr_date
Field Type	text
Valid Field	mm-dd-yyyy
Directives	<p>Linked to <i>Was there any recurrence of tumor in the ipsilateral chest wall or in mastectomy scars, in the ipsilateral supraclavicular, infraclavicular, axillary, or internal mammary nodes?</i></p> <p>If '1, Yes' was recorded to the LRR question, complete. Record the first date of loco-regional recurrence for the breast cancer. The date of loco-regional recurrence should correspond to the first indication of recurrence based on either imaging or pathology results.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10)

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	If '0, No' was recorded to the LRR question, leave blank.
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	LRR Date Interval, in Days - Automated
REDCap Variable Name	lrr_date_int
Field Type	Calculated: datediff([dob_date],[lrr_date],'d', 'mdy', false)
Directives	<p>Dependent upon LRR Date.</p> <p>If the Follow-up Date was entered, REDCap will calculate this field by subtracting the Date of Birth from the LRR Date.</p> <p>If the LRR Date was not entered, this data field will remain blank.</p>
Identifier?	N
Required Field?	N
Field Label	Site of LRR
REDCap Variable Name	lrr_site
Field Type	radio
Choice List	1, Local only 2, Regional Lymph Nodes only 3, Local and Regional Lymph Nodes
Directives	<p>Linked to Was there any recurrence of tumor in the ipsilateral chest wall or in mastectomy scars, in the ipsilateral supraclavicular, infraclavicular, axillary, or internal mammary nodes?</p> <p>If '1, Yes' was recorded to the LRR question, complete. Record the first site of LRR.</p> <p>If '0, No' was recorded to the LRR question, leave blank.</p>
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Distant Metastatic Diagnosis (de novo or relapsed) Sub-Section

Abstracting Notes:

1. Use this section to record data concerning the first distant metastases. If sites are identified at the same time or within the 30 days, count them as the first distant sites.
2. Use imaging reports like CT scans or MRIs and medical oncology provider notes to identify the first distant metastatic sites. Defer to the medical oncologist's clinical assessment for an indication of metastasis.
3. Some usual sites of distant metastases for breast cancer include: bone, liver, lung, and brain.
 - If the patient's primary breast cancer diagnosis is Stage IV, record the distant metastases that were present at diagnosis.
 - If the patient's primary breast cancer diagnosis is Stage I-III, record the first distant metastases occurring after the primary diagnosis timeframe.
4. If you have any questions or concerns about the identification of distant metastases, please contact the Center PI.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Date of radiologically confirmed Distant Metastatic Disease Today M-D-Y
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Distant Metastatic Disease Interval [View equation](#)

Was a biopsy performed of metastatic site? Yes No reset

Did the ER/PR/HER2 status differ (positive to negative or vice versa) from primary tumor? Yes No reset

PR status: POSITIVE = (>1%)

ER Status POSITIVE = (>1%)

HER2 Status POSITIVE= (IHC 3+ / FISH > 2)

Site of First Distant Metastatic Disease

	Yes	No	Unknown	
Bone	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	reset
Liver	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	reset
Lung	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	reset
Brain	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	reset
Lymph Node	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	reset
Soft Tissue	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	reset
Other	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	reset

Field Label	Date of Radiologically Confirmed Distant Metastatic Disease
REDCap Variable Name	distant_mets_disease_date
Field Type	text
Valid Field	mm-dd-yyyy
Directives	<p>Record the first date that a distant metastatic site was identified by imaging for the breast cancer.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<ul style="list-style-type: none"> If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> For winter use January (1) For spring use April (4) For summer use July (7) For autumn use October (10) <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Distant Metastatic Disease Interval, in Days - Automated
REDCap Variable Name	mets_disease_date_int
Field Type	Calculated: datediff([dob_date],[distant_mets_disease_date],'d', 'mdy', false)
Directives	<p>Dependent upon <i>Date of Radiologically Confirmed Distant Metastatic Disease.</i></p> <p>If the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> was entered, REDCap will calculate this field by subtracting the <i>Date of Birth</i> from the <i>Date of Radiologically Confirmed Distant Metastatic Disease.</i></p>
Identifier?	N
Required Field?	N
Field Label	Was a biopsy performed of metastatic site?
REDCap Variable Name	biopsy_yn
Field Type	yesno
Directives	<p>Record 'Yes' if a biopsy was taken from one or more of the first distant sites. Biopsies can include incisional biopsies, excisional biopsies, needle biopsies, FNAs, and aspirations.</p> <p>If you are unsure as to whether or not a patient had a biopsy of a metastatic site (e.g. patient could have had biopsy at outside institution), and your institution has no documentation indicating a that biopsy of a metastatic site was performed there or elsewhere, enter 'No'.</p>
Identifier?	N
Required Field?	N
Field Label	Did the ER/PR/HER2 status differ (positive to negative or vice versa) from primary tumor?
REDCap Variable Name	receptor_status_change
Field Type	yesno
Directives	Linked to <i>Was a biopsy performed of metastatic site?</i> - if the response is 'Yes' <i>Did the ER/PR/HER2 status differ (positive to negative or vice versa) from primary tumor?</i> becomes active.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	Record 'Yes' if ER or PR or HER2 status changed from that which was recorded for the primary tumor. Only one of the three needs to change in order to record 'Yes.'
Identifier?	N
Required Field?	N
Field Label	PR Status Change
REDCap Variable Name	receptor_change_pr
Field Type	dropdown
Choice List	1, Positive 2, Negative 99, UNK
	Linked to <i>Did the ER/PR/HER2 status differ (positive to negative or vice versa) from primary tumor?</i> If the response is 'Yes' PR Status Change becomes active. Record '1, Positive' if the distant site is noted in the pathology report to be positive for progesterone receptors. If the PR status is reported as a percentage greater than 1%, record '1, Positive.' If PR status is reported as less than or equal to 1%, record '2, Negative.' If the pathology report for the biopsy of the distant met is not available, but the treating physician states that the metastatic site is positive for progesterone receptors, record '1, Positive.' Directives If the pathology report does not include PR status, report '99. UNK.'
Identifier?	N
Required Field?	N
Field Label	ER Status Change
REDCap Variable Name	receptor_change_er
Field Type	dropdown
Choice List	1, Positive 2, Negative 3, UNK
	Linked to <i>Did the ER/PR/HER2 status differ (positive to negative or vice versa) from primary tumor?</i> If the response is 'Yes' ER Status Change becomes active. Record '1, Positive' if the distant site is noted in the pathology report to be positive for estrogen receptors. If the ER status is reported as a percentage greater than 1%, record '1, Positive.' If ER status is reported as less than or equal to 1%, record '2, Negative.' If the pathology report for the biopsy of the distant met is not available, but the treating physician states that the metastatic site is positive for estrogen receptors, record '1, Positive.' Directives If the pathology report does not include PR status, report '99. UNK.'
Identifier?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Required Field?	N
Field Label	HER2 Status Change
REDCap Variable Name	receptor_change_her2
Field Type	dropdown
Choice List	1, Positive 2, Negative 99, UNK
	<p>Linked to <i>Did the ER/PR/HER2 status differ (positive to negative or vice versa) from primary tumor?</i> If the response is 'Yes' HER2 Status Change becomes active. Record '1, Positive' if the primary breast tumor is noted in the pathology report to be positive for HER2 by IHC at 3+ or FISH>2.</p> <p>If the HER2 is reported by IHC at 2+ and FISH was either not done or was done but reported as Equivocal record '2, Equivocal;'</p> <p>Anything else is "0, Negative", for e.g HER2 IHC 2+ but FISH is non-amplified.</p> <p>If the pathology reports for the biopsy of the distant met is not available, but the treating physician records that the breast cancer is HER2 positive record '1, Positive.'</p>
Directives	If the pathology report does not include PR status, report '99. UNK.'
Identifier?	N
Required Field?	N
Field Label	Met Site: Bone
REDCap Variable Name	bone_yn
Field Type	radio
Choice List	1, Yes 0, No 99, Unknown
	<p>Linked to <i>Date of Radiologically Confirmed Distant Metastatic Disease.</i> Use this date to determine whether metastasis to the bone is found within 30 days of the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> – if so, the bone is a first distant site of metastasis.</p> <p>If the breast cancer first metastasized to the bone, record '1, Yes.'</p> <p>If there is no evidence that the breast cancer metastasized to the bone at the time of the first distant metastasis, record '0, No.'</p> <p>If the evidence is equivocal like the imaging report states that the bone is questionable, record '99, Unknown.'</p>
Directives	
Identifier?	N
Required Field?	N
Field Label	Met Site: Liver
REDCap Variable Name	liver_yn
Field Type	Radio

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Choice List	1, Yes 0, No 99, Unknown
Directives	<p>Linked to <i>Date of Radiologically Confirmed Distant Metastatic Disease</i>. Use this date to determine whether metastasis to the liver is found within 30 days of the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> – if so, the liver is a first distant site of metastasis.</p> <p>If the breast cancer first metastasized to the liver, record ‘1, Yes.’</p> <p>If there is no evidence that the breast cancer metastasized to the liver at the time of the first distant metastasis, record ‘0, No.’</p> <p>If the evidence is equivocal like the imaging report states that the liver is questionable, record ‘99, Unknown.’</p>
Identifier?	N
Required Field?	N
Field Label	Met Site: Lung
REDCap Variable Name	lung_yn
Field Type	Radio
Choice List	1, Yes 0, No 99, Unknown
Directives	<p>Linked to <i>Date of Radiologically Confirmed Distant Metastatic Disease</i>. Use this date to determine whether metastasis to the lung is found within 30 days of the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> – if so, the lung is a first distant site of metastasis.</p> <p>If the breast cancer first metastasized to the lung, record ‘1, Yes.’</p> <p>If there is no evidence that the breast cancer metastasized to the lung at the time of the first distant metastasis, record ‘0, No.’</p> <p>If the evidence is equivocal like the imaging report states that the lung is questionable, record ‘99, Unknown.’</p>
Identifier?	N
Required Field?	N
Field Label	Met Site: Brain
REDCap Variable Name	brain_yn
Field Type	Radio
Choice List	1, Yes 0, No 99, Unknown
Directives	<p>Linked to <i>Date of Radiologically Confirmed Distant Metastatic Disease</i>. Use this date to determine whether metastasis to the brain is found within 30 days of the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> – if so, the brain is a first distant site of metastasis.</p> <p>If the breast cancer first metastasized to the brain, record ‘1, Yes.’</p>

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>If there is no evidence that the breast cancer metastasized to the brain at the time of the first distant metastasis, record '0, No.'</p> <p>If the evidence is equivocal like the imaging report states that the brain is questionable, record '99, Unknown.'</p>
Identifier?	N
Required Field?	N
Field Label	Met Site: Lymph Node (do not include local or regional)
REDCap Variable Name	lymph_yn
Field Type	Radio
Choice List	1, Yes 0, No 99, Unknown
Directives	<p>Linked to <i>Date of Radiologically Confirmed Distant Metastatic Disease</i>. Use this date to determine whether metastasis to a lymph node is found within 30 days of the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> – if so, the lymph node is a first distant site of metastasis.</p> <p>If the breast cancer first metastasized to the lymph node, record '1, Yes.'</p> <p>If there is no evidence that the breast cancer metastasized to the lymph node at the time of the first distant metastasis, record '0, No.'</p> <p>If the evidence is equivocal like the imaging report states that the lymph node is questionable, record '99, Unknown.'</p>
Identifier?	N
Required Field?	N
Field Label	Met Site: Soft Tissue
REDCap Variable Name	Soft_tissue_yn
Field Type	Radio
Choice List	1, Yes 0, No 99, Unknown
Directives	<p>Linked to <i>Date of Radiologically Confirmed Distant Metastatic Disease</i>. Use this date to determine whether metastasis to soft tissue is found within 30 days of the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> – if so, the soft tissue is a first distant site of metastasis.</p> <p>If the breast cancer first metastasized to the soft tissue, record '1, Yes.'</p> <p>If there is no evidence that the breast cancer metastasized to the soft tissue at the time of the first distant metastasis, record '0, No.'</p> <p>If the evidence is equivocal like the imaging report states that the soft tissue is questionable, record '99, Unknown.'</p>
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Field Label	Met Site: Other Site
REDCap Variable Name	other_yn
Field Type	Radio
Choice List	1, Yes 0, No 99, Unknown
Directives	<p>Linked to <i>Date of Radiologically Confirmed Distant Metastatic Disease</i>. Use this date to determine whether metastasis to a site that is not listed is found within 30 days of the <i>Date of Radiologically Confirmed Distant Metastatic Disease</i> – if so, this other site is a first distant site of metastasis.</p> <p>If the breast cancer first metastasized to a site that is not listed, record ‘1, Yes.’</p> <p>If there is no evidence that the breast cancer metastasized to another at the time of the first distant metastasis, record ‘0, No.’</p> <p>If the evidence is equivocal like the imaging report states that the other site is questionable, record ‘99, Unknown.’</p>
Identifier?	N
Required Field?	N
Field Label	Met Site: Which Site?
REDCap Variable Name	mets_site
Field Type	text
Directives	<p>Linked to Met Site: Other Site. If the response is ‘Yes,’ Met Site: Which Site? becomes active.</p> <p>Record the other site of first distant metastasis.</p>
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Other (Non-Breast) Cancer Diagnoses Sub-Section

Abstracting Notes:

1. Other cancer diagnoses should be entered into this section; up to three diagnoses can be entered.
2. The other cancers can be diagnosed either prior to or following the breast cancer diagnosis that is eligible for this study.
3. The other cancers should be invasive.
4. Do not record pre-cancerous or non-invasive cancers.

Other (Non-Breast) Cancer Diagnoses

Has the patient had another (non-Breast) cancer diagnosis? Yes No reset

Number of non-Breast cancer diagnoses:

Non-Breast Diagnosis Oncotree Code: Please [see here](#) for Onco-Tree Code by disease type.

Non-Breast Diagnosis Oncotree Code: Please [see here](#) for Onco-Tree Code by disease type.

Non-Breast Diagnosis Oncotree Code: Please [see here](#) for Onco-Tree Code by disease type.

Form Status

Complete?

Field Label	Has the patient had another (non-Breast) cancer diagnosis?
REDCap Variable Name	nonbreast_ca_dx_yn
Field Type	Yesno
Directives	If the patient has had one or more invasive cancer diagnoses, record 'Yes.' If the patient has not had another invasive cancer diagnosis, record 'No'
Identifier?	N
Required Field?	N
Field Label	Number of non-Breast cancer diagnoses
REDCap Variable Name	nonbreast_ca_dx_number
Field Type	Text
Valid Field	1-100
Directives	Linked to <i>Has the patient had another (non-Breast) cancer diagnosis?</i> If the response is 'Yes' then <i>Number of non-Breast cancer diagnoses</i> becomes active.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Identifier?	N
Required Field?	N
Field Label	Non-Breast Diagnosis Oncotree Code, Number 1
REDCap Variable Name	non_breast_oncotree_code_1
Field Type	Text
Directives	Linked to <i>Has the patient had another (non-Breast) cancer diagnosis?</i> If the response is 'Yes' then <i>Non-Breast Diagnosis Oncotree Code</i> becomes active. Please refer to http://www.cbioportal.org/oncotree/ for Onco-Tree Code by disease type.
Identifier?	N
Required Field?	N
Field Label	Non-Breast Diagnosis Oncotree Code, Number 2
REDCap Variable Name	non_breast_oncotree_code_2
Field Type	Text
Directives	Linked to <i>Has the patient had another (non-Breast) cancer diagnosis?</i> If the response is 'Yes' then <i>Non-Breast Diagnosis Oncotree Code</i> becomes active. Please refer to http://www.cbioportal.org/oncotree/ for Onco-Tree Code by disease type.
Identifier?	N
Required Field?	N
Field Label	Non-Breast Diagnosis Oncotree Code, Number 3
REDCap Variable Name	non_breast_oncotree_code_3
Field Type	Text
Directives	Linked to <i>Has the patient had another (non-Breast) cancer diagnosis?</i> If the response is 'Yes' then <i>Non-Breast Diagnosis Oncotree Code</i> becomes active. Please refer to http://www.cbioportal.org/oncotree/ for Onco-Tree Code by disease type.
Identifier?	N
Required Field?	N
Field Label	Form Status: Complete?
REDCap Variable Name	
Field Type	Dropdown
Choice List	Incomplete Unverified Complete
Directives	Record 'Complete' once all of the data fields in this section have been entered and the eligibility calculation has been performed. This field will be used during data quality review. 'Incomplete' is the default choice; patients with any indication of 'Incomplete' or

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	'Unverified' sections are not eligible for data analysis.
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

TUMOR SAMPLE SEQUENCING INFORMATION

Abstracting Notes:

2. Some of the data fields found in this section should be provided by Sage through a download of each center's GENIE data submission.
3. The set of data elements in this section should be completed for each specimen sampled and submitted to GENIE.
 - a. The last question in the set 'Was another sample sequenced in this patient?' will drive the data collection. If 'Yes' is answered, then another set of data fields will appear for the next sample.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Tumor Sample Sequencing Information

Re-assign this record to another Data Access Group? DFC

Editing existing Record ID 1 - 1a

Record ID 1

Sample 1

Date sample was collected: M-D-Y
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Sample Date Interval

Sample Type

Date of the Sequencing Report M-D-Y
DEFINED AS THE DATE THE REPORT OF TUMOR SEQUENCING WAS ISSUED*

Sequence Report Date Interval

GENIE Sample ID (if available):

Sequencing Method

PR status
POSITIVE = (> 1%)

HER2 Status
POSITIVE= (IHC 3+/FISH>2), EQUIVOCAL=(IHC 2+)

ER Status
POSITIVE = (> 1%)

AKT Mutation Status
* must provide value

ERBB2 Mutation Status
* must provide value

ESR1 Mutation Status:
* must provide value

PIK3CA Mutation Status:
* must provide value

Was another sample sequenced in this patient? Yes No

Form Status

Complete?

Field Label	Date sample was collected
REDCap Variable Name	sample_date_1
Field Type	text
Valid Field	mm-dd-yyyy
Directives	Record the date that the sequenced sample was actually collected for sequencing (i.e. biopsy or surgery date). Note that the actual date of sample collection can often be years before the sample is sent for sequencing.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10) <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Sample Date Interval – Automated
REDCap Variable Name	sample_date_int_1
Field Type	Calculated: datediff([dob_date],[sample_date_1], 'd', 'mdy', false)
Directives	
Identifier?	N
Required Field?	N
Field Label	Sample Type
REDCap Variable Name	sample_type_1
Field Type	dropdown
Choice List	1, Primary tumor 2, Lymph node metastasis 3, Distant organ metastasis 4, Metastasis site unspecified 5, Local recurrence 6, Not otherwise specified 7, Primary, local recurrence, or metastasis
Directives	This data can be imported using the center’s GENIE submission; if this is not available the data field should be entered by the data abstractor. If the data field is not pre-populated, record the sample type.
Identifier?	N
Required Field?	N
Field Label	Date of the Sequencing Report
REDCap Variable Name	sequence_report_date_1
Field Type	text
Valid Field	mm-dd-yyyy
Directives	This data can be imported using the center’s GENIE submission; if this is not available

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>the data field should be entered by the data abstractor.</p> <p>If the data field is not pre-populated, record the date that the sequencing report was issued.</p> <p>This date should be known and not be estimated.</p> <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Sequence Report Date Interval - Automated
REDCap Variable Name	sequence_report_date_int_1
Field Type	Calculated: datediff([dob_date],[sequence_report_date_1],'d', 'mdy', false)
Directives	
Identifier?	N
Required Field?	N
Field Label	GENIE Sample ID (if available)
REDCap Variable Name	genie_sample_id_1
Field Type	text
Directives	This data can be imported using the center's GENIE submission; if this is not available the data field should be entered by the data abstractor.
Identifier?	N
Required Field?	N
Field Label	Sequencing Method
REDCap Variable Name	sequence_method_1
Field Type	dropdown
Choice List	1, Sequenom 2, Miseq 3, Sanger 98, Other
Directives	This data can be imported using the center's GENIE submission; if this is not available the data field should be entered by the data abstractor.
Directives	Record the sequencing method. If the method used does not appear in the list, record '98, Other.'
Identifier?	N
Required Field?	N
Field Label	Specify Sequence Method
REDCap Variable Name	other_sequence_method_1

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Field Type	text
	<p>This data can be imported using the center’s GENIE submission; if this is not available the data field should be entered by the data abstractor.</p> <p>Linked to Sequencing Method.</p> <p>If ‘98, Other’ is recorded for Sequencing Method, record the method used for sequencing or test name for e.g. Foundation One, local institution sequencing platform like MSK-IMPACT, etc.</p>
Directives	If this not accessible, ask the Center PI for details.
Identifier?	N
Required Field?	N
Field Label	Progesterone Receptor – PR status of the Sequenced Sample
REDCap Variable Name	pr_status_1
Field Type	dropdown
Choice List	1, Positive 0, Negative 99, UNK
	Record ‘1, Positive’ if the sequenced sample is noted in the pathology report to be positive for progesterone receptors. If the PR is reported as a percentage greater than 1%, record ‘1, Positive.’
Directives	If PR status of the sequenced sample is not noted, record ‘99, UNK.’
Identifier?	N
Required Field?	N
Field Label	HER2 Status of the Sequenced Sample
REDCap Variable Name	her2_status
Field Type	Dropdown
Choice List	1, Positive 0, Negative 2, Equivocal 99, UNK
	Record ‘1, Positive’ if the sequenced sample noted in the to be positive for HER2 by IHC at 3+ or FISH>2.
	If the HER2 status is reported by IHC at 2+ or 1+, record ‘2, Equivocal;’ additionally, if the HER2 is reported as FISH 1 or 2, record ‘2, Equivocal.’
Directives	If HER2 status of the sequenced sample is not noted in the pathology report or by physician report, record ‘99, UNK.’
Identifier?	N
Required Field?	N
Field Label	Estrogen Receptor – ER status of the Sequenced Sample
REDCap Variable Name	er_status
Field Type	Dropdown
Choice List	1, Positive 0, Negative 99, UNK
Directives	Record ‘1, Positive’ if the sequenced sample is noted to be positive for estrogen

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	receptors. If the ER is reported as a percentage greater than 1%, record '1, Positive.' If ER status of the sequenced sample is not noted, record '99, UNK.'
Identifier?	N
Required Field?	N
Field Label	AKT Mutation Status
REDCap Variable Name	akt_mutation_status_1
Field Type	dropdown
Choice List	1, Mutant 2, Wildtype
	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor. If an AKT1 E17K mutation is identified, select '1, Mutant.'
Directives	If no AKT1 E17K mutation is identified, 'select 2, Wildtype.'
Identifier?	N
Required Field?	N
Field Label	AKT Variant 1
REDCap Variable Name	akt_variant_1_sample_1
Field Type	text
	This data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor. If the answer to "AKT Mutation Status" was "1, Mutant" (i.e. an AKT 1 E17K mutation was identified), the variant is entered here. When annotating AKT1 variants, use the cDNA nomenclature, as provided by Sage. e.g. AKT1 variant E17K should be entered as AKT1 variant c.49G>A
Directives	
Identifier?	N
Required Field?	N
Field Label	AKT Variant 2
REDCap Variable Name	akt_variant_2_sample_1
Field Type	text
	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor. This section is to capture if a rare patient with an AKT1 E17K mutation also has another mutation in AKT1. When annotating AKT1 variants, use the cDNA nomenclature, as provided by Sage.
Directives	
Identifier?	N
Required Field?	N
Field Label	ERBB2 Mutation Status

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

REDCap Variable Name	erbb2_mutation_status_1
Field Type	dropdown
Choice List	1, Mutant 2, Wildtype 99, UNK
Directives	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.
Identifier?	N
Required Field?	N
Field Label	ERBB2 Variant
REDCap Variable Name	erbb2_variant_1
Field Type	text
Choice List	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.
Directives	
Identifier?	N
Required Field?	N
Field Label	ESR1 Mutation Status
REDCap Variable Name	esr1_mutation_status_1
Field Type	dropdown
Choice List	1, Mutant 2, Wildtype 99, UNK
Directives	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.
Identifier?	N
Required Field?	N
Field Label	ESR1 Variant
REDCap Variable Name	esr1_variant_1
Field Type	text
Directives	The data for this field may be imported using the center's GENIE submission; if this does not occur, the data should be entered by the data abstractor.
Identifier?	N
Required Field?	N
Field Label	PIK3CA Mutation Status
REDCap Variable Name	pik3ca_mutation_status_1
Field Type	dropdown

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Choice List	1, Mutant 2, Wildtype 99, UNK
Directives	The data for this field may be imported using the center’s GENIE submission; if this does not occur, the data should be entered by the data abstractor.
Identifier?	N
Required Field?	N
Field Label	PIK3CA Variant
REDCap Variable Name	pik3ca_variant_1
Field Type	text
Directives	The data for this field may be imported using the center’s GENIE submission; if this does not occur, the data should be entered by the data abstractor.
Identifier?	N
Required Field?	N
Field Label	Was another (breast cancer) sample sequenced in this patient?
REDCap Variable Name	sampleseq2_yn
Field Type	yesno
Directives	<p>If the patient has another breast cancer sample sequenced, record ‘Yes.’ This could be the primary breast tumor or metastases from the breast cancer.</p> <p>A ‘Yes’ will activate data fields for Sample 2.</p> <p>If the patient has no other samples, record ‘No.’</p> <p>If the patient has another sample with a non breast cancer OncoTree code (for e.g if the patient also has a separate lung cancer or sarcoma etc, record ‘No.’</p> <p>Do not leave blank.</p>
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

TREATMENT REGIMENS

Abstraction Notes:

1. Cancer directed drug therapies will be entered into different sections according to disease state:
 - a. Primary Diagnosis Treatment with details on hormone therapy
 - b. LRR Treatment with details on hormone therapy
 - c. Metastatic Diagnosis Therapy with details on chemotherapy
2. Each single drug should be entered separately, even if it was administered as part of a regimen.

Primary Diagnosis: Treatment Regimen

1. Use the EMR to look for cancer-directed drug therapies; use the Medications and the provider notes to locate the details of drug therapies.
2. The receipt of chemotherapy will be recorded, but the actual chemotherapies will not be recorded.
3. The receipt of hormone therapy will be recorded, and the actual hormone therapies will be recorded; up to three drugs can be entered,
4. The data guide will provide directives for the first treatment; subsequent treatments will be similar.

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Treatment Regimens Re-assign this record to another Data Access Group? DFC ▼

✎ Editing existing Record ID 1 - 1a

Record ID 1

Was Chemotherapy (CT) received after primary diagnosis date but before LRR or distant metastatic date? Yes ▼

Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date? Yes ▼

DIRECTIONS:

- IF APPROXIMATED BY 15, USE FIRST OF THE MONTH AS DEFAULT.
- IF DRUG HAS NOT BEEN DISCONTINUED, ENTER DATE THE DRUG WAS LAST ADMINISTERED.
- IF A PATIENT HAS HAD A "TREATMENT BREAK" - WHEREBY THEY START, STOP (FOR <=3 MONTHS) AND THEN RE-START THE SAME DRUG, ONLY RECORD START AND FINAL STOP DATE FOR THAT DRUG.
- IF MULTIPLE REASONS EXIST FOR DRUG DISCONTINUATION, POD TAKES PRECEDENCE

Primary Diagnosis: Treatment Regimen 1

Was this administered as part of a combination therapy with ovarian suppression or other? Yes
 No reset

Therapy 1: ▼

Therapy 1 Start Date: Today M-D-Y
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Therapy 1 Start Interval: View equation

Therapy 1 End Date: Today M-D-Y
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Therapy 1 End Interval: View equation

Was drug discontinued Yes
 No reset

Field Label	Was Chemotherapy (CT) received after primary diagnosis date but before LRR or distant metastatic date?
REDCap Variable Name	chemo_therapy_postdx
Field Type	dropdown
Choice List	1, Yes 0, No 99, UNK
Directives	If the patient received CT after the primary diagnosis but before LRR, record '1, Yes.' If the patient did not receive CT after the primary diagnosis but before LRR, record

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>'No.'</p> <p>In the case that a patient transfers care to your center after the primary diagnosis and it is not certain that the patient receive CT, record '99, UNK.'</p>
Identifier?	N
Required Field?	N
Field Label	Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?
REDCap Variable Name	hormo_therapy_postdx
Field Type	dropdown
Choice List	1, Yes 0, No 99, UNK
Directives	<p>If the patient received HT after the primary diagnosis but before LRR, record '1, Yes.'</p> <p>If the patient did not receive HT after the primary diagnosis but before LRR, record 'No.'</p> <p>In the case that a patient transfers care to your center after the primary diagnosis and it is not certain that the patient receive HT, record '99, UNK.'</p>
Identifier?	N
Required Field?	N
Field Label	Was this administered as part of a combination therapy with ovarian suppression or other?
REDCap Variable Name	combo_therapy1_yn
Field Type	yesno
Directives	<p>Linked to <i>Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?</i> If the response is 'Yes' then <i>Was this administered as part of a combination therapy with ovarian suppression or other?</i> becomes active.</p> <p>If the hormone therapy was administered with ovarian suppression or similar, record 'Yes.' If not, record 'No.'</p> <p>Do not leave blank.</p>
Identifier?	N
Required Field?	N
Field Label	Therapy 1
REDCap Variable Name	hormone_1
Field Type	dropdown
Choice List	1, Ovarian suppression/ablation therapyv (Leuprolide/Goserelin/ BSO) 2, Anastrozole 3, Letrozole 4, Exemestane 5, Fulvestrant 6, Tamoxifen 7,

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	Toremifene 8, Megestrol acetate 9, Flouxymesterone 10, Ethinyl estradiol 98, Other
	Linked to <i>Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?</i> If the response is 'Yes' then <i>Therapy 1</i> becomes active. Choose the hormone therapy received by the patient from the drop-down list. If the hormone therapy is not listed, record '98, Other.' If the drug is not listed, record its name. In rare instances, patients may receive hormone therapy in combination with a non-hormonal agent.
Directives	Do not leave blank.
Identifier?	N
Required Field?	N
Field Label	Was this administered as part of the clinical trial?
REDCap Variable Name	hormone1_clintrial
Field Type	yesno
	Linked to <i>Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?</i> If the response is 'Yes' then <i>Was this administered as part of the clinical trial?</i> becomes active Record 'Yes' if the hormone therapy was administered as a part of a clinical trial. Please note that it is not necessary for the hormone therapy to be evaluated in the trial in order to record 'Yes.'
Directives	
Identifier?	N
Required Field?	N
Field Label	Therapy 1, Specify
REDCap Variable Name	hormone1_other
Field Type	text
	Linked to <i>Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?</i> If the response is 'Yes' then <i>Therapy1, Specify</i> becomes active. Linked to <i>Therapy 1</i> . If the response is '98, Other' record the hormone therapy that is not listed in the drop-down list. Please make sure that the drug recorded is an actual hormone therapy.
Directives	
Identifier?	N
Required Field?	N
Field Label	Therapy 1 Start Date
REDCap Variable Name	hormo1_start

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Field Type	text
Valid Field	mm-dd-yyyy
	<p>Linked to <i>Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?</i> If the response is 'Yes' then <i>Therapy 1, Start Date</i> becomes active.</p> <p>Record the date that the drug was first administered to the patient.</p> <p>Note for oral medications: If the first date of administration is not known, record the date the drug was prescribed or ordered or recorded in medical notes as date of therapy initiation.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10)
Directives	Do not leave blank.
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Therapy 1 Start Interval
REDCap Variable Name	hormo1_start_int
Field Type	Calculated: datediff([dob_date],[reg2_hormo1_start],'d', 'mdy', false)
	<p>Linked to <i>Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?</i> If the response is 'Yes' then <i>Therapy 1, Start Date Interval</i> becomes active.</p> <p>Dependent upon <i>Therapy1 Start Date</i>.</p> <p>If the <i>Therapy1 Start Date</i> was entered, REDCap will calculate this field by subtracting the <i>Date of Birth</i> from the <i>Therapy1 Start Date</i>.</p>
Directives	If the <i>Therapy1 Start Date</i> was not entered, this data field will remain blank.
Identifier?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Required Field?	N
Field Label	Therapy 1 End Date
REDCap Variable Name	hormo1_end
Valid Field	mm-dd-yyyy
Choice List	text
	<p>Record the last date that the patient received the medication.</p> <p>If the actual last date that the drug was administered is not documented, record the date that the provider stated was the last date of administration in the EMR.</p> <p>If a patient leaves your institutional care and you are no longer certain of when a therapy was discontinued, enter the last known date of therapy administration at your institution.</p> <p>If a drug has not been discontinued, enter the date that the drug was last administered at the time of data abstraction.</p> <p>If a patient has a treatment break or holiday, whereby she starts a hormone therapy and stops the drug for less than or equal to 3 months (90 days) and then re-starts the same medication, record the first start date for Therapy 1 Start Date and the final end date for the therapy as Therapy 1 End Date.</p> <p>If a patient has a treatment break or holiday, whereby she starts a hormone therapy and stops the drug for greater than 3 months (90 days) and then re-starts the same medication, record the first start date and the first end date for Therapy 1 End Date; record the same drug in Therapy 2 with the second start date and the final end date for the therapy.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10)
Directives	Do not leave blank.
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Field Label	Therapy 1 End Interval
REDCap Variable Name	hormo1_end_int
Field Type	Calculated: datediff([dob_date],[reg2_hormo1_start],'d', 'mdy', false)
Directives	<p>Dependent upon Therapy1 End Date.</p> <p>If the Therapy1 End Date was entered, REDCap will calculate this field by subtracting the Date of Birth from the Therapy1 End Date.</p> <p>If the Therapy1 End Date was not entered, this data field will remain blank.</p>
Identifier?	N
Required Field?	N
Field Label	Was drug discontinued?
REDCap Variable Name	hormo1_discon_yn
Field Type	treatment_regimens
Choice List	Yesno
Directives	<p>Record 'Yes' if the hormone therapy has been discontinued.</p> <p>If the hormone therapy has not been discontinued at the time of data abstraction, record 'No.'</p>
Identifier?	N
Required Field?	N
Field Label	Reason for Discontinuation
REDCap Variable Name	hormo1_reason
Field Type	Dropdown
Choice List	0, Completion of Planned Therapy 1, Toxicity 2, Patient Preference 3, Not Effective/Progression of Disease 99, Other/UNK
Directives	<p>Linked to Was drug discontinued? If 'Yes' record the reason that the hormone therapy was discontinued.</p> <p>If 'No' leave blank.</p> <p>If a patient leaves your institutional care and you are no longer certain of when a therapy was discontinued, enter 'Lost to follow-up'.</p> <p>If multiple reason exist for drug discontinuation and one of the reasons is for disease progression, record '3, Not Effective/Progression of Disease.'</p>
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

LRR: Treatment Regimens

1. Use the EMR to look for cancer-directed drug therapies; use the Medications and the provider notes to locate the details of drug therapies.
2. The receipt of chemotherapy following LRR will be recorded, but the actual chemotherapies will not be recorded.
3. The receipt of hormone therapy following LRR will be recorded, and the actual hormone therapies will be recorded; up to three drugs can be entered,
4. The data guide will provide directives for the first treatment in the first regimen; subsequent treatments have similar directives.

- IF DRUG HAS NOT BEEN DISCONTINUED, ENTER DATE THE DRUG WAS LAST ADMINISTERED.
- IF A PATIENT HAS HAD A "TREATMENT BREAK" - WHEREBY THEY START, STOP (FOR <=3 MONTHS) AND THEN RE-START THE SAME DRUG, ONLY RECORD START AND FINAL STOP DATE FOR THAT DRUG.
- IF MULTIPLE REASONS EXIST FOR DRUG DISCONTINUATION, POD TAKES PRECEDENCE

LRR Treatment Regimens

Was CT received after LRR date but before distant metastatic diagnosis date?

Was HT received after LRR date but before distant metastatic diagnosis date

LRR Diagnosis: Treatment Regimen 1

Was this administered as part of a combination therapy with ovarian suppression or other? Yes No reset

Therapy 1:

Therapy 1 Start Date: M-D-Y
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Therapy 1 Start Interval:

Therapy 1 End Date: M-D-Y
PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!

Therapy 1 End Interval:

Was drug discontinued Yes No reset

Field Label	Was CT received after LRR date but before distant metastatic diagnosis date?
REDCap Variable Name	lrr_chemo_therapy_postdx
Field Type	Dropdown

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Choice List	1, Yes 0, No 99, UNK
	If the patient received CT following a LRR and before a diagnosis of a distant metastasis, record '1, Yes.' If the patient did not receive CT following the LRR, record 'No.' In the case that a patient transfers care to your center after the LRR and it is not certain that the patient receive CT following the LRR, record '99, UNK.'
Directives	
Identifier?	N
Required Field?	N
Field Label	Was HT received after LRR date but before distant metastatic diagnosis date?
REDCap Variable Name	lrr_hormo_therapy_postdx
Field Type	Dropdown
Choice List	1, Yes 0, No 99, UNK
	If the patient received HT following a LRR, record '1, Yes.' If the patient did not receive HT following the LRR, record 'No.' In the case that a patient transfers care to your center after the LRR and it is not certain that the patient receive HT following the LRR, record '99, UNK.'
Directives	
Identifier?	N
Required Field?	N
Field Label	Was this administered as part of a combination therapy with ovarian suppression or other?
REDCap Variable Name	lrr_combo_therapy1_yn
Field Type	Yesno
	Linked to <i>Was HT received after LRR date but before distant metastatic diagnosis date?</i> If the response is 'Yes' then <i>Was this administered as part of a combination therapy with ovarian suppression or other?</i> becomes active. If the hormone therapy was administered with ovarian suppression or similar, record 'Yes.' If not, record 'No.'
Directives	Do not leave blank.
Identifier?	N
Required Field?	N
Field Label	Therapy 1
REDCap Variable Name	lrr_hormone_1
Field Type	Dropdown
Choice List	1, Ovarian suppression/ablation therapyv (Leuprolide/Goserelin/ BSO) 2, Anastrozole 3, Letrozole 4, Exemestane 5, Fulvestrant 6, Tamoxifen 7,

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	Toremifene 8, Megestrol acetate 9, Fluoxymesterone 10, Ethinyl estradiol 98, Other
	Linked to <i>Was HT received after LRR date but before distant metastatic diagnosis date?</i> If the response is 'Yes' then <i>Therapy 1</i> becomes active. Choose the hormone therapy received by the patient from the drop-down list. If the hormone therapy is not listed, record '98, Other.' If the drug is not listed, please make sure that it is a hormone therapy. If it is not, do not record in this field.
Directives	Do not leave blank.
Identifier?	N
Required Field?	N
Field Label	Was this administered as part of the clinical trial?
REDCap Variable Name	lrr_hormone1_clintrial
Field Type	Yesno
	Linked to <i>Was HT received after LRR date but before distant metastatic diagnosis date?</i> If the response is 'Yes' then <i>Was this administered as part of the clinical trial?</i> becomes active. Record 'Yes' if the hormone therapy was administered as a part of a clinical trial. Please note that it is not necessary for the hormone therapy to be evaluated in the trial in order to record 'Yes.'
Directives	
Identifier?	N
Required Field?	N
Field Label	Therapy 1, Specify
REDCap Variable Name	lrr_hormone1_other
Field Type	Text
	Linked to <i>Was HT received after LRR date but before distant metastatic diagnosis date?</i> If the response is 'Yes' then <i>Therapy1, Specify</i> becomes active. Linked to <i>Therapy 1</i> . If the response is '98, Other' record the hormone therapy that is not listed in the drop-down list. Please make sure that the drug recorded is an actual hormone therapy.
Directives	
Identifier?	N
Required Field?	N
Field Label	Therapy 1 Start Date
REDCap Variable Name	lrr_hormo1_start
Field Type	Text
Valid Field	mm-dd-yyyy
Directives	Linked to <i>Was HT received after LRR date but before distant metastatic diagnosis</i>

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>date? If the response is 'Yes' then Therapy 1, Start Date becomes active.</p> <p>Record the date that the drug was first administered to the patient.</p> <p><u>Note for oral medications:</u> If the first date of administration is not known, record the date the drug was prescribed or ordered or ordered in medical notes as date of therapy initiation.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10) <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Therapy 1 Start Interval
REDCap Variable Name	lrr_hormo1_start_int
Field Type	Calculated: datediff([dob_date],[reg2_hormo1_start],'d', 'mdy', false)
	<p>Linked to Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date? If the response is 'Yes' then Therapy 1, Start Date Interval becomes active.</p> <p>Dependent upon Therapy1 Start Date.</p> <p>If the Therapy1 Start Date was entered, REDCap will calculate this field by subtracting the Date of Birth from the Therapy1 Start Date.</p>
Directives	If the Therapy1 Start Date was not entered, this data field will remain blank.
Identifier?	N
Required Field?	N
Field Label	Therapy 1 End Date
REDCap Variable Name	lrr_hormo1_end
Valid Field	mm-dd-yyyy

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Choice List	text
	<p>Linked to Was HT received after LRR date but before distant metastatic diagnosis date? If the response is 'Yes' then Therapy 1, End Date becomes active.</p> <p>Record the last date that the patient received the medication.</p> <p>If the actual last date that the drug was administered is not documented, record the date that the provider stated was the last date of administration in the note.</p> <p>If a patient leaves your institutional care and you are no longer certain of when a therapy was discontinued, enter the last known date of therapy administration at your institution.</p> <p>If a drug has not been discontinued, enter the date that the drug was last administered at the time of data abstraction.</p> <p>If a patient has a treatment break or holiday, whereby she starts a hormone therapy and stops the drug for less than or equal to 3 months (90 days) and then re-starts the same medication, record the first start date for Therapy 1 Start Date and the final end date for the therapy as Therapy 1 End Date.</p> <p>If a patient has a treatment break or holiday, whereby she starts a hormone therapy and stops the drug for greater than 3 months (90 days) and then re-starts the same medication, record the first start date and and the first end date for Therapy 1 End Date; record the same drug in Therapy 2 with the second start date and the final end date for the therapy.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10)
Directives	Do not leave blank.
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Therapy 1 End Interval

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

REDCap Variable Name	lrr_hormo1_end_int
Field Type	Calculated: datediff([dob_date],[reg2_hormo1_start],'d','mdy',false)
	Linked to Was HT received after LRR date but before distant metastatic diagnosis date? If the response is 'Yes' then Therapy 1, End Date Interval becomes active. Dependent upon Therapy1 End Date . If the Therapy1 End Date was entered, REDCap will calculate this field by subtracting the Date of Birth from the Therapy1 End Date .
Directives	If the Therapy1 End Date was not entered, this data field will remain blank.
Identifier?	N
Required Field?	N
Field Label	Was drug discontinued?
REDCap Variable Name	lrr_hormo1_discon_yn
Field Type	treatment_regimens
Choice List	yesno
	Linked to Was HT received after LRR date but before distant metastatic diagnosis date? If the response is 'Yes' then Was drug discontinued becomes active. Record 'Yes' if the hormone therapy has been discontinued prior to the time of data abstraction. If the hormone therapy has not been discontinued at the time of data abstraction, record 'No.'
Directives	
Identifier?	N
Required Field?	N
Field Label	Reason for Discontinuation
REDCap Variable Name	lrr_hormo1_reason
Field Type	dropdown
Choice List	0, Completion of Planned Therapy 1, Toxicity 2, Patient Preference 3, Not Effective/Progression of Disease 99, Other/UNK
	Linked to Was drug discontinued? If 'Yes' record the reason that the hormone therapy was discontinued. If 'No' leave blank. If a patient leaves your institutional care and you are no longer certain of when a therapy was discontinued, enter 'Lost to follow-up'.
Directives	If multiple reason exist for drug discontinuation and one of the reasons is for disease

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	progression, record '3, Not Effective/Progression of Disease.'
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Metastatic Diagnosis: Therapy

Abstraction Notes:

1. Record all of the drugs given in the setting of distant metastases.
2. A portion of the data fields is provided below as an example; these types of data fields will be abstracted for each cancer-directed drug therapy received by the patient.

Metastatic Diagnosis: Therapy 1	
Does this therapy involve a combination regimen?	<input checked="" type="radio"/> Yes <input type="radio"/> No reset
How many drugs are part of the therapy	<input type="text"/> ▼
Drug 1	<input type="text"/> ▼
Start Date	<input type="text"/> Today M-D-Y <small>PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!</small>
Therapy 1 Drug 1 Start Interval	<input type="text"/> View equation
End Date	<input type="text"/> Today M-D-Y <small>PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!</small>
Therapy 1 Drug 1 End Interval	<input type="text"/> View equation
Has this drug been discontinued?	<input type="radio"/> Yes <input type="radio"/> No reset
Metastatic Diagnosis: Therapy 2	
Does this therapy involve a combination regimen?	<input type="radio"/> Yes <input type="radio"/> No reset
Drug 1	<input type="text"/> ▼
Start Date	<input type="text"/> Today M-D-Y <small>PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!</small>
Therapy 2 Drug 1 Start Interval	<input type="text"/> View equation
End Date	<input type="text"/> Today M-D-Y <small>PLEASE ENTER DATE IN MM - DD - YYYY FORMAT!</small>
Therapy 2 Drug 1 End Interval	<input type="text"/> View equation
Has this drug been discontinued?	<input type="radio"/> Yes <input type="radio"/> No reset
Metastatic Diagnosis: Therapy 3	

Data Abstraction Guide for all cancer-directed drug therapies within each combination regimens for distant metastases.

Field Label	Does this therapy involve a combination regimen?
REDCap Variable Name	therapy1_combo_yn
Field Type	yesno

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	Record 'Yes' two or more cancer-directed drugs are given as a regimen.
Directives	If one cancer directed drug is given, record 'No.'
Identifier?	N
Required Field?	N
Field Label	How many drugs are part of the therapy?
REDCap Variable Name	therapy1_combo_num
Field Type	dropdown
Choice List	1, 2 2, 3 3, 4
Directives	Linked to <i>Does this therapy involve a combination regimen?</i> If the response is 'Yes' Record the number of cancer-directed drugs in the therapy. This data field will control the number of drugs that you can enter for the first line of therapy.
Identifier?	N
Required Field?	N
Field Label	Drug 1
REDCap Variable Name	therapy1_drug1
Field Type	Dropdown
Choice List	1, Doxorubicin 2, Pegylated liposomal doxorubicin 3, Paclitaxel 4, Capecitabine 5, Gemcitabine 6, Vinorelbine 7, Eribulin 8, Cyclophosphamide 9, Carboplatin 10, Docetaxel 11, Albumin-bound paclitaxel 12, Cisplatin 13, Epirubicin 14, Ixabepilone 15, Trastuzumab 16, Pertuzumab 17, Ado-trastuzumab emtansine 18, Lapatinib 19, Ovarian suppression/ablation therapy (Leuprolide/Goserelin/ BSO) 20, Anastrozole 21, Letrozole 22, Exemestane 23, Fulvestrant 24, Tamoxifen 25, Toremifene 26, Megestrol acetate 27, Flouxymesterone 38, Ethinyl estradiol 29, Exemestane 30, Everolimus 31, Palbociclib 98, Other
Directives	Choose the first drug in the therapy regimen. If the drug is not listed, record '98, Other.'
Identifier?	N
Required Field?	N
Field Label	Was this administered as part of the clinical trial?
REDCap Variable Name	therapy1_drug1_clintrial
Field Type	Yesno
Directives	Record 'Yes' if the drug therapy was administered as a part of a clinical trial. Please note that it is not necessary for the drug to be evaluated in the trial in order to record 'Yes.'
Identifier?	N
Required Field?	N
Field Label	Was the drug AZD5363?

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

REDCap Variable Name	therapy1_drug1_azd5363
Field Type	yesno
Directives	If Drug 1 is AZD5363, record 'Yes' else record 'No.'
Identifier?	N
Required Field?	N
Field Label	Generic name of drug
REDCap Variable Name	therapy1_drug1_other
Field Type	Text
Directives	Linked to Drug . if '98, Other' is noted, record the generic name of the drug. If '98, Other' is not noted, leave blank.
Identifier?	N
Required Field?	N
Field Label	Therapy 1 Start Date
REDCap Variable Name	therapy1_drug1_start
Field Type	Text
Valid Field	mm-dd-yyyy
Directives	<p>Linked to Was therapy received after primary diagnosis date but before LRR or distant metastatic date? If the response is 'Yes' then Therapy 1, Start Date becomes active.</p> <p>Record the date that the drug was first administered to the patient.</p> <p><u>Note for oral medications:</u> If the first date of administration is not known, record the date the drug was prescribed or ordered or recorded in medical notes as date of therapy initiation.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10) <p>Do not leave blank.</p>

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10) <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Therapy 1 Start Interval
REDCap Variable Name	therapy1_drug1_start_int
Field Type	Calculated: datediff([dob_date],[reg2_hormo1_start],'d', 'mdy', false)
Directives	<p>Linked to <i>Was Hormone therapy (HT) received after primary diagnosis date but before LRR or distant metastatic date?</i> If the response is 'Yes' then <i>Therapy 1, Start Date Interval</i> becomes active.</p> <p>Dependent upon <i>Therapy1 Start Date</i>.</p> <p>If the <i>Therapy1 Start Date</i> was entered, REDCap will calculate this field by subtracting the <i>Date of Birth</i> from the <i>Therapy1 Start Date</i>.</p> <p>If the <i>Therapy1 Start Date</i> was not entered, this data field will remain blank.</p>
Identifier?	N
Required Field?	N
Field Label	Therapy 1 End Date
REDCap Variable Name	therapy1_drug1_end
Valid Field	mm-dd-yyyy
Choice List	text
Directives	<p>Record the last date that the patient received the medication.</p> <p>If the actual last date that the drug was administered is not documented, record the date that the provider stated was the last day of administration in the medical notes.</p> <p>If a patient leaves your institutional care and you are no longer certain of when a</p>

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

	<p>therapy was discontinued, enter the last known date of therapy administration at your institution.</p> <p>If a drug has not been discontinued, enter the date that the drug was last administered at the time of data abstraction.</p> <p>If a patient has a treatment break or holiday, whereby she starts a hormone therapy and stops the drug for less than or equal to 3 months (90 days) and then re-starts the same medication, record the first start date for Therapy 1 Start Date and the final end date for the therapy as Therapy 1 End Date.</p> <p>If a patient has a treatment break or holiday, whereby she starts a hormone therapy and stops the drug for greater than 3 months (90 days) and then re-starts the same medication, record the first start date and the first end date for Therapy 1 End Date; record the same drug in Therapy 2 with the second start date and the final end date for the therapy.</p> <p>If the full date is not known, estimate the date on using the components that are known.</p> <ul style="list-style-type: none"> • If month and year of the date is known, and the day of the month is not known, record 15 for the day. • If year of the date is known, and the day and month is not known, record 6 (June) for the month and 15 for the day. • If the year is known, and the seasons are noted rather than the month and day, use the following: <ul style="list-style-type: none"> ○ For winter use January (1) ○ For spring use April (4) ○ For summer use July (7) ○ For autumn use October (10) <p>Do not leave blank.</p>
Identifier?	Y; this data element will not be shared with MSK. It will be used to calculate the interval in days.
Required Field?	N
Field Label	Therapy 1 End Interval
REDCap Variable Name	therapy1_drug1_end_int
Field Type	Calculated: datediff([dob_date],[reg2_hormo1_start],'d', 'mdy', false)
Directives	<p>Dependent upon Therapy1 End Date.</p> <p>If the Therapy1 End Date was entered, REDCap will calculate this field by subtracting the Date of Birth from the Therapy1 End Date.</p> <p>If the Therapy1 End Date was not entered, this data field will remain blank.</p>
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Field Label	Was drug discontinued?
REDCap Variable Name	therapy1_drug1_discon_yn
Field Type	treatment_regimens
Choice List	yesno
Directives	Record 'Yes' if the hormone therapy has been discontinued. If the hormone therapy has not been discontinued at the time of data abstraction, record 'No.'
Identifier?	N
Required Field?	N
Field Label	Reason for Discontinuation
REDCap Variable Name	therapy1_drug1_reason
Field Type	dropdown
Choice List	0, Completion of Planned Therapy 1, Toxicity 2, Patient Preference 3, Not Effective/Progression of Disease 99, Other/UNK
Directives	Linked to Was drug discontinued? If 'Yes' record the reason that the hormone therapy was discontinued. If 'No' leave blank. If a patient leaves your institutional care and you are no longer certain of when a therapy was discontinued, enter 'Lost to follow-up'. If multiple reason exist for drug discontinuation and one of the reasons is for disease progression, record '3, Not Effective/Progression of Disease.'
Identifier?	N
Required Field?	N
Field Label	Form Status: Complete?
REDCap Variable Name	
Field Type	Dropdown
Choice List	Incomplete Unverified Complete
Directives	Record 'Complete' once all of the data fields in this section have been entered and the eligibility calculation has been performed. This field will be used during data quality review. 'Incomplete' is the default choice; patients with any indication of 'Incomplete' or 'Unverified' sections are not eligible for data analysis.
Identifier?	N
Required Field?	N

Data Abstraction Guide: GENIE AKT1 Breast Cancer Project

Appendix One: AJCC 7th Edition, Staging Guidelines

The patients should be staged using the AJCC 7th Edition Guidelines. Here is a quick reference for Breast Cancer

<https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf>